LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

Search

Amicus Therapeutics Inc

Chiusa

SettoreSettore sanitario

6.07 -2.41

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

6.07

Massimo

6.11

Metriche Chiave

By Trading Economics

Entrata

-36M

-22M

Vendite

-24M

125M

EPS

0.03

Margine di Profitto

-17.314

Dipendenti

499

EBITDA

-27M

-4.8M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+166.89% upside

Dividendi

By Dow Jones

Utili prossimi

7 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-355M

1.9B

Apertura precedente

8.48

Chiusura precedente

6.07

Notizie sul Sentiment di mercato

By Acuity

50%

50%

151 / 381 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Amicus Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

31 mag 2025, 10:30 UTC

Notizie principali

Pension Funds Won't Save the Bond Market -- Heard on the Street -- WSJ

31 mag 2025, 06:30 UTC

Utili

5 Things We've Learned From Retail Earnings -- Barrons.com

31 mag 2025, 04:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

30 mag 2025, 23:51 UTC

Acquisizioni, Fusioni, Takeovers

Trump Raises Steel Tariffs, Saying U.S. Steel Will Remain U.S.-Controlled -- Update

30 mag 2025, 21:30 UTC

Notizie principali

Stocks Shrug Off Trade War to Post Best Month Since 2023 -- WSJ

30 mag 2025, 21:15 UTC

Notizie principali

The Score: E.l.f. Beauty, Tesla, Nvidia, and More Stocks That Defined the Week -- WSJ

30 mag 2025, 20:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Health Care Roundup: Market Talk

30 mag 2025, 20:44 UTC

Acquisizioni, Fusioni, Takeovers

Bill Ackman Is Killing It. A New ETF Will Track His Investments. -- Barrons.com

30 mag 2025, 20:24 UTC

Notizie principali

Major U.S. Stock Indexes Finish About Flat; U.S.-China Trade Friction Renews -- WSJ

30 mag 2025, 20:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

30 mag 2025, 19:44 UTC

Discorsi di Mercato

Gold Breaks 4-Month Winning Streak -- Market Talk

30 mag 2025, 19:38 UTC

Discorsi di Mercato

Companies Delay or Cancel $14B In Clean-Energy Investments -- Market Talk

30 mag 2025, 19:29 UTC

Utili
Acquisizioni, Fusioni, Takeovers

NRG Energy and UnitedHealth Are the S&P 500's Best and Worst for May. Here's Why. -- Barrons.com

30 mag 2025, 19:14 UTC

Discorsi di Mercato

Oil Settles Lower Ahead of OPEC+ Output Decision -- Market Talk

30 mag 2025, 19:05 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Fall Awaiting Hotter Weather -- Market Talk

30 mag 2025, 18:51 UTC

Discorsi di Mercato

Canada's Retaliatory Tariffs Help Fuel Sizable Rise in Tax Revenue -- Market Talk

30 mag 2025, 18:37 UTC

Discorsi di Mercato
Utili

Costco Well Positioned for Sustainable Growth, UBS Says -- Market Talk

30 mag 2025, 18:04 UTC

Notizie principali

S&P 500 Falls After More Trump-China Friction -- WSJ

30 mag 2025, 17:47 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

30 mag 2025, 17:47 UTC

Discorsi di Mercato

Time for BoC Gov. Macklem to Cut Rates, Desjardins Says -- Market Talk

30 mag 2025, 17:40 UTC

Acquisizioni, Fusioni, Takeovers

Trump Is Praising His U.S. Steel Deal. No One Is Sure What It Means -- WSJ

30 mag 2025, 17:38 UTC

Discorsi di Mercato

U.S: Oil Rig Count Falls for Fifth Straight Week -- Market Talk

30 mag 2025, 17:31 UTC

Discorsi di Mercato

Costco Well Positioned to Gain Share Amid Tariffs, Baird Says -- Market Talk

30 mag 2025, 17:14 UTC

Notizie principali

American Consumers Are Still Gloomy on the Economy -- 3rd Update

30 mag 2025, 16:31 UTC

Utili

Ulta Beauty Stock Is Rising. Earnings Strength Was More Than Cosmetic. -- Barrons.com

30 mag 2025, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

30 mag 2025, 16:20 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Health Care Roundup: Market Talk

30 mag 2025, 16:16 UTC

Notizie principali

S&P 500 Falls After Trump Hits Out at China -- WSJ

30 mag 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

30 mag 2025, 16:14 UTC

Notizie principali

HSBC Retreats From Banking Smaller U.S. Businesses -- WSJ

Confronto tra pari

Modifica del prezzo

Amicus Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

166.89% in crescita

Previsioni per 12 mesi

Media 16.2 USD  166.89%

Alto 22 USD

Basso 12 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Amicus Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

7 ratings

5

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

5.925 / 7.38Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

151 / 381 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.